The Largest Personal Injury Firm in Texas. Serving Clients Nationwide.
Austin 512-520-0221 Corpus Christi 361-254-7873 San Antonio 210-874-2615 Nationwide Toll Free 866-517-5659
Contact us 24/7 Contact us 24/7

Our attorneys and staff continue to work through COVID-19 and remain available 24/7, ready to fight for you. Our video conferencing, case management, and telecommunications systems allow us to stay in constant contact with our clients and pursue their claims without interruption – all without our clients leaving the comfort of their homes. You focus on staying healthy and safe, we’re here to handle the rest.

Daclatasvir Studies

Hep C Clinical Trials- The Daclatasvir Studies

Thomas J. Henry is actively investigating reports of injuries and serious adverse events linked to clinical trials for Bristol-Meyers Squibb’s experimental hepatitis C drug Daclatasvir (formerly BMS-790052).

After abandoning the development of BMS-986094 as a possible combination drug to be taken with Daclatasvir due to reports of heart failure and heart and kidney toxicity, BMS began looking for other possible combinations in an effort to develop the first all oral hepatitis C treatment. Clinical trial data suggests that some patients may have suffered injury as a result of these combination studies.


  • Daclatasvir is a NS5A inhibitor being developed by Bristol-Meyers Squibb in the hopes that it could potentially replace current hepatitis C treatments.
  • In efforts to maximize anti-HCV activity, the drug is often combined with other hepatitis C treatments with the goal of boosting results.
  • According to the Hepatitis C Trust, Daclatasvir has been tested in conjunction with the following drugs:


  • In 2012, the results of clinical trial AI444040 were presenting at the American Association for the Study of Liver Disease Meeting (AAASLD 2012).
  • According to CATIE, Daclatasvir was tested in combination with Sofosbuvir both with and without ribavarin in a Phase 2 clinical trial.
  • While the drug was praised for its high success rate in some of the most hard to treat cases of hepatitis C, it did not come entirely free of complications.
  • A release by CATIE reports that a number of participants suffered adverse effects including:
    • Stroke
    • Fibromyalgia
    • Fractures
    • Lung Pain
    • Kidney Failure
    • Intestinal Inflammation


Contact Us for a FREE Case Review

866-517-5659 •

Do you really want to end conversation?
chat-icon Live chat
avatar Waiting